drugset / Trial / NCT03132519

Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation

NCT03132519

Phase 4 Completed 364 enrolled Fundacion Clinica Valle del Lili
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Pain, cough, hypertension and tachycardia are frequent events during extubation due to a secondary stimulation of mechanoreceptors located in the airway. The mechanical effect of the endotracheal tube activates autonomic reflexes, a situation that could potentially impair the clinical condition of patients. Previous studies have used remifentanil during emergence and extubation showing good results to control this reflex response. However, it is unknown so far, the optimal effect site concentration (Ce) of remifentanil to allow a better control of these events with a low incidence of adverse effects after have received inhaled anesthesia plus remifentanil for anesthetic maintenance. This study will determine the Ce of remifentanil associated with a lower proportion of cough and hyperdynamic circulatory response during extubation for emergency after exposure to sevoflurane or desflurane.

Timeline

Start
2013-10
Primary completion
2015-11
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 1 ng/ml
Subject Remifentanil Small molecule 2 ng/ml
Subject Remifentanil Small molecule 2.5 ng/ml

Indications